Kathleen Moore to Antineoplastic Agents
This is a "connection" page, showing publications Kathleen Moore has written about Antineoplastic Agents.
Connection Strength
2.082
-
PARP inhibitor associated treatment related myeloid neoplasms: What was a "Rare" complication may be less so. Gynecol Oncol. 2021 06; 161(3):639-641.
Score: 0.491
-
Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States. Gynecol Oncol. 2018 11; 151(2):190-195.
Score: 0.408
-
Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. Oncologist. 2018 06; 23(6):697-703.
Score: 0.394
-
Outcomes of cervical cancer and positive para-aortic lymph nodes in the modern era of chemoradiation. Int J Gynecol Cancer. 2014 Mar; 24(3):564-9.
Score: 0.297
-
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models. Sci Rep. 2019 12 11; 9(1):18882.
Score: 0.111
-
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018 12 27; 379(26):2495-2505.
Score: 0.102
-
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clin Cancer Res. 2018 07 15; 24(14):3263-3272.
Score: 0.099
-
Applying a computer-aided scheme to detect a new radiographic image marker for prediction of chemotherapy outcome. BMC Med Imaging. 2016 08 31; 16(1):52.
Score: 0.088
-
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014 Feb; 32(1):87-93.
Score: 0.070
-
MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634.
Score: 0.023